Shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Get Free Report) were up 6.6% during trading on Thursday . The company traded as high as $22.02 and last traded at $22.6570. 185,349 shares changed hands during trading, a decline of 88% from the average daily volume of 1,607,998 shares. The stock had previously closed at $21.25.
More PROCEPT BioRobotics News
Here are the key news stories impacting PROCEPT BioRobotics this week:
- Neutral Sentiment: Multiple law firms are publicizing the same pending securities class action covering investors who purchased PRCT shares between February 28, 2024, and February 25, 2026. The lead-plaintiff application deadline is September 22, 2026. These announcements are largely procedural and do not represent separate confirmed lawsuits. Kaplan Fox class-action deadline notice
- Neutral Sentiment: Recent notices from Pomerantz, Kaplan Fox, DJS Law Group, Rosen Law Firm, and other firms encourage affected shareholders to contact them or seek lead-plaintiff status. The legal process could ultimately result in investor compensation, but no outcome or settlement has been announced. Pomerantz investor alert
- Negative Sentiment: The core complaint centers on allegedly undisclosed inventory problems, weaker-than-expected handpiece sales, and repeated late-quarter discounts. One notice attributes the lawsuit to an approximately 18% stock decline following revelations about these issues, highlighting investor concerns about demand visibility, channel inventory, and management disclosures. Hagens Berman securities-fraud lawsuit notice
Analyst Ratings Changes
PRCT has been the topic of several research analyst reports. Leerink Partners cut PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $31.00 to $29.00 in a report on Thursday, June 11th. Wall Street Zen raised PROCEPT BioRobotics from a "strong sell" rating to a "sell" rating in a research note on Saturday, April 25th. Weiss Ratings reissued a "sell (e+)" rating on shares of PROCEPT BioRobotics in a research note on Friday, July 17th. Evercore set a $23.00 target price on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. Finally, Piper Sandler dropped their target price on shares of PROCEPT BioRobotics from $35.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, PROCEPT BioRobotics presently has an average rating of "Hold" and a consensus target price of $28.00.
Get Our Latest Report on PRCT
PROCEPT BioRobotics Trading Up 3.0%
The company has a current ratio of 6.55, a quick ratio of 5.35 and a debt-to-equity ratio of 0.15. The company has a fifty day moving average price of $21.29 and a two-hundred day moving average price of $24.56. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -11.28 and a beta of 0.89.
PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The company had revenue of $94.50 million during the quarter, compared to analyst estimates of $92.77 million. During the same period in the prior year, the business posted ($0.35) EPS. PROCEPT BioRobotics's revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, research analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Larry L. Wood bought 23,900 shares of the business's stock in a transaction on Friday, August 7th. The stock was acquired at an average cost of $20.85 per share, with a total value of $498,315.00. Following the purchase, the chief executive officer directly owned 23,900 shares of the company's stock, valued at $498,315. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders sold 1,000 shares of company stock valued at $28,480. 4.00% of the stock is owned by company insiders.
Institutional Investors Weigh In On PROCEPT BioRobotics
Several hedge funds and other institutional investors have recently bought and sold shares of PRCT. BlackRock Inc. purchased a new stake in shares of PROCEPT BioRobotics in the 2nd quarter valued at approximately $109,961,000. Alliancebernstein L.P. lifted its holdings in PROCEPT BioRobotics by 58.6% in the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company's stock valued at $122,052,000 after acquiring an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its holdings in PROCEPT BioRobotics by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company's stock valued at $102,919,000 after acquiring an additional 1,218,815 shares during the last quarter. Mackenzie Financial Corp grew its position in PROCEPT BioRobotics by 8.2% in the fourth quarter. Mackenzie Financial Corp now owns 1,573,405 shares of the company's stock worth $49,512,000 after acquiring an additional 118,971 shares during the period. Finally, Artisan Partners Limited Partnership increased its stake in PROCEPT BioRobotics by 11.4% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,520,700 shares of the company's stock worth $47,841,000 after acquiring an additional 155,601 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.
PROCEPT BioRobotics Company Profile
(
Get Free Report)
PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.
The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider PROCEPT BioRobotics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PROCEPT BioRobotics wasn't on the list.
While PROCEPT BioRobotics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
